Pancreatic ductal adenocarcinomas (PDACs) are considered to arise through neoplastic transformation of human pancreatic duct epithelial cells (HPDECs). In order to evaluate the biological significance of genetic and epigenetic alterations in PDACs, we isolated primary HPDECs and established an in vitro carcinogenesis model.
Firstly, lentivirus-mediated transduction of KRAS

G12V
, MYC and human papillomavirus 16 (HPV16) E6/E7 under the control of a tetracyclin-inducible promoter efficiently immortalized and transformed primary HPDECs, which gave rise to adenocarcinomas subcutaneously in an immune-deficient mouse xenograft model, depending on expression of the four genes. The tumors regressed promptly upon shutting-off the oncogenes, and the remaining tissues showed histological features corresponding to normal ductal structures with simple columnar epithelium. Reexpression of the oncogenes resulted in development of multiple PDACs through pancreatic intraepithelial neoplasia-like structures. We also succeeded in efficient immortalization of primary HPDECs with transduction of mutant CDK4, cyclin D1 and TERT. The cells maintained a normal diploid status and formed duct-like structures in a threedimensional culture. In combination with p53 silencing, KRAS
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human cancers. It is characterized by late diagnosis due to lack of early symptoms, extensive metastasis and high resistance to chemotherapy and radiation. Despite advances in the clinical management of the disease, only ~6% of patients survive 5 years after diagnosis and prognosis of PDAC remains poor (1) (2) (3) (4) . Further work is needed to elucidate the events driving pancreatic carcinogenesis to have any hope of eventually conquering this disease.
Although the cells-of-origin for PDAC remain controversial, a multistep carcinogenesis process has become widely accepted. In this concept, PDAC arises from precursor lesions termed Pancreatic Intraepithelial Neoplasia (PanIN) involving multiple genetic alterations. Four genes, KRAS (>90%), p16/CDKN2A (>95%), p53 (50-75%) and DPC4/SMAD4 (55%) are found to be commonly mutated or inactivated in PDAC (1) (2) (3) . These are classified as driver alterations for development of PDAC.
Genetically engineered mouse models of PDAC are excellent experimental systems which have helped to improve our understanding of the disease. In these models, invasive cancers that resemble human PDAC can be induced by combinations of two or three genetic alterations in precursors of mouse pancreas (5) . However, there are biological differences between mice and humans. Since the altered expression of the genes is sufficient to produce metastatic cancers, limits exist as to the capacity to investigate new candidate cancer gene functions. Therefore, other approaches using human materials, such as human pancreatic cancer cell lines and human normal pancreatic cells, are also needed, in addition to the use of genetically engineered mouse models.
Recently, we have established in vitro multistep carcinogenesis models for cervical cancer, epithelial ovarian cancer and oral cancer (6) (7) (8) . In the present study, taking advantage of this background, we could successfully immortalize and transform primary human pancreatic duct epithelial cells with defined genetic elements. Using a tetracyclin-inducible system, we found, for the first time, that bimodal expression of oncogenes brings out reversible features of transformation and recurrence of multiple PDACs through PanIN-like structures. Unique features and applications of this approach are discussed.
Materials and methods
Isolation of human pancreatic duct epithelial cells
Normal human pancreatic tissues were obtained with written consent from patients who underwent abdominal surgery for a pancreaticobiliary diseases. Human pancreatic duct epithelial cell (HPDEC4) was obtained from pancreas tail of a patient who underwent resection for pancreatic head carcinoma. No cancerous lesions near the specimen were confirmed by histopathological examination. HPDEC6 and HPDEC 7-11 were obtained from patients who underwent resection for solid pseudopapillary neoplasm and ampullary cancer, respectively. The pancreas tissue was confirmed macroscopically normal with no pathological lesions by pathologists, minced into pieces suspended in Hanks' balanced salt solution with 1 mg/ml Liberase HI (Roche) and incubated at 37°C for 60 min. The dissociated tissues were subsequently filtered with a 70 μm pores Cell Strainer (BD Biosciences) and isolated primary epithelial cells were seeded on type I collagen-coated dishes (Corning). HPDECs were maintained in serum-free keratinocyte serum-free medium (Invitrogen) supplemented with 5 ng/ml epidermal growth factor (Sigma), 50 μg/ml of bovine pituitary extract (Hammond CELL TECH), 10% fetal bovine serum, 2 mM NAC (N-Acetyl-L-cysteine; Wako), 0.2 mM Asc-2P (L-ascorbic acid 2-phosphate; Wako), which is similar to the K-NAC medium described earlier (9) , but further supplemented with 5 μM Y-27632 (Selleck Chemicals).
Pancreatic cancer cell lines
Pancreatic cancer cell lines, AsPC-1, BxPC-3, Capan-1, Capan-2, HPAC, PANC-1 and MIAPaCa-1, were obtained from ATCC and grown in Dulbecco's modified Eagle's medium (DMEM; Nacalai tesque) containing 10% fetal bovine serum. These cell lines have not been authenticated by the authors.
Vector construction and retroviral infection Oncogenic KRAS (KRAS
G12V
) and a mutant form of MYC (MYC T58A ) generated by site-directed mutagenesis were cloned and recombined into retroviral expression vectors to generate pCLXSN-KRAS G12V and pCMSCVpuro-MYC T58A , as described previously (8) . A retroviral vector pCL-SI-MSCVhyg-H1R-p53shRNA was designed to express a p53-specific short Abbreviations: DOX, doxycyclin; HPDEC, human pancreatic duct epithelial cell; HPV16, human papillomavirus 16; PanIN, Pancreatic Intraepithelial Neoplasia; shRNA, short hairpin RNA.
A novel human cancer xenograft model for pancreatic duct adenocarcinoma hairpin RNA (shRNA) targeting 5′-GACTCCAGTGGTAATCTAC-3′ (10) . Lentiviral vectors expressing TERT, cyclin D1 and mutant CDK4 (CDK4
R24C
: an inhibitor resistant form of CDK4) were constructed by recombination with a lentiviral vector, CSII-CMV-RfA as described previously (8) . CSII-TRE-TightRfA was generated by replacing the elongation factor promoter in CSII-EFRfA with the tetracycline-responsive promoter from pTRE-Tight (Clontech ) segments separated by sequences encoding the autonomous 'self-cleaving' 2A peptides derived from foot-and-mouse disease virus into CSII-TRE-Tight-RfA. The production of recombinant viruses was as detailed earlier (8, 11) .
Ethics statement
Tissues from patients: Normal human pancreatic tissues were obtained with written consent from patients. The study was approved by the National Cancer Center Institutional Review Board. Animal study: Animal studies were carried out according to the Guideline for Animal Experiments in National Cancer Center, which meet the ethical standards required by the law and the guidelines about experimental animals in Japan, and approved by the Committee for Ethics in Animal Experimentation of the National Cancer Center. Cell line information: Pancreatic cancer cell lines, AsPC-1, BxPC-3, Capan-1, Capan-2, HPAC, PANC-1 and MIAPaCa-1, were directly obtained from ATCC. Among them AsPC-1, BxPC-3, PANC-1 and MIAPaCa-1 were purchased in 1993, and AsPC-1, BxPC-3, PANC-1 and MIAPaCa-1 were purchased in 2009. They have been passaged and used in our laboratory for <6 months after resuscitation though these cell lines have not been authenticated by the authors.
Western analysis
Western blotting was conducted as described previously (8) . Antibodies used were listed in the Supplementary Materials and methods, available at Carcinogenesis Online.
G-banding karyotyping analysis
The karyotype analysis was carried out using standard G-banding by an outsourced service (Mitsubishi Chemical Medience).
Three-dimension culture for HPDECs
The three-dimensional culture protocol was a modification of the procedure described previously (12) . Briefly, cells were embedded in type I collagen (final 2 mg/ml solution, AteloCell IPC; Koken) alone or in a mixture of type I collagen (final 2 mg/ml) and Matrigel (final 2 mg/ml, 354248; BD Biosciences) mixed with growth medium containing 10 mM HEPES. Cells were cultivated in the gel on a cell culture insert (353494, FALCON) dipped in growth medium for 3-4 weeks. For histological analysis, cultures were fixed with 10% neutral buffered Formalin (4% formaldehyde) and embedded in paraffin.
Immunohistochemical examination
Formalin-fixed and paraffin-embedded tissue sections were deparaffinized in xylene and rehydrated through a graded ethanol series (100-70%). For antigen retrieval, slides were immersed in a citrate buffer (pH 6.4) or Target Retrieval Solution (pH9) (S2367; Dako). The slides were then incubated in methanol containing 0.3% H 2 O 2 to inhibit endogenous peroxidase activity. After washing, primary antibodies were applied for 1 h and binding was detected using an Envision Kit (Dako). Color development was achieved with 3, 3′-diaminobenzidine as chromogen and hematoxylin counterstaining.
Tumorigenesis in Nude Mice
All surgical procedures and care of the animals were in accordance with institutional guidelines. A 100 μl volume of 10 6 cells in a 1:1 mixture of Matrigel (354248; BD Biosciences) was subcutaneously injected into female BALB/c nude mice (Clea Japan). Doxycyclin (DOX) was given to the recipient mice via their drinking water (1 mg/ml in 5% sucrose). Tumor size was measured every other day using calipers and tumor volume was estimated using the following formula: V = (LW 2 )/2, where V, volume (mm 3 ); L, largest diameter (mm) and W, smallest diameter (mm).
Results
Conditional tumorigenic transformation of primary HPDECs with human papillomavirus type 16 E6/E7, MYC and oncogenic RAS G12V
Previously, we demonstrated that introduction of human papillomavirus type 16 (HPV 16) E6 and E7 genes (E6E7), oncogenic HRAS (HRAS
G12V
) and MYC (MYC T58A ) is sufficient for tumorigenic transformation of normal human cells, such as cervical keratinocytes, tongue keratinocytes and bronchial epithelial cells (6-8). Here, a single polycistronic vector designed to express E6E7, MYC and KRAS G12V (EMR) under control of a tetracycline-responsive promoter was transduced into a strain of primary HPDEC6 together with the tetracyclin-dependent transcriptional activator (tetOFF) ( Figure 1A ). DOX-dependent silencing of the oncogenes was confirmed by western blotting. The growth of HPDEC6 cells depended on expression of the transgenes ( Figure 1B and C). When transduced cells were subcutaneously transplanted into nude mice, they formed tumors within 1 month (Table I, Figure 1D ). Most parts of the resultant tumors showed histological features corresponding to moderately to poorly differentiated adenocarcinoma ( Figure 1E , left panel) and some parts of periphery of the tumors showed those corresponding to well-differentiated adenocarcinoma ( Figure 1E , middle panel). When the tumors became evident, DOX was administered to animals and this resulted in halted tumor growth, followed by almost complete regression. Close examination of the remaining tissues showed ductal structures consisting of simple columnar epithelium ( Figure 1E , right panel). The epithelial cells derived from HPDEC maintained quasinormal duct structures for at least 1 month in subcutaneous sites of mice without any sign of tumor growth.
After confirmation of regression of initial tumors, DOX was withdrawn to examine whether tumors regrew or not. About 2 months after the withdrawal, overt tumors reappeared at the sites of initial tumors. Interestingly, a mixed histology composed of simple columnar cells and malignant cells was observed in the reformed tumors (Supplementary Figure 1C , available at Carcinogenesis Online).
In a genetic engineered tumor model of Rattus pancreas, expression of oncogenic Kras or Hras induces pancreatic cancer, whereas in human lesions, oncogenic KRAS mutations are most common (13) . In our xenograft model, HRAS G12V showed essentially the same results as obtained with KRAS G12V (Figure 1D and E; Supplementary Figure 1A , available at Carcinogenesis Online). We confirmed the tumorigenic effects of the oncogenes by employing another independent batch of HPDEC derived from other patients (Supplementary Figure 1B , available at Carcinogenesis Online). These results support that oncogenic RAS signaling plays a crucial role in pancreatic cancer development.
Temporal analyses of PDAC development from quasinormal tissues derived from HPDEC
To more precisely characterize the histological features of the tumors and to analyze the temporal development of tumors from quasinormal ductal structures, tumors were collected and examined at different time points before and after DOX administration, and after withdrawal of DOX.
As in the pilot experiment described above, initial tumors appeared within 1 month, and the tumor volume exceeded 300 mm 3 within 20 days, when DOX was administered. After the initial tumors regressed to masses <150 mm 3 , DOX was withdrawn. Reproducibility of not only the initial tumor growth but also the regression and regrowth of the tumors was excellent, judging from the standard error bars of the tumor sizes of individual animals and even tumor sizes for different animals ( Figure 2A ). The initial tumors were confirmed to exhibit moderately to poorly differentiated adenocarcinoma histology ( Figure 2B ). Immunohistochemical analyses indicated that the tumors expressed MUC1 and MUC5AC, which are also widely expressed in human PDAC clinical samples. On the other hand, expression of CDX-2 and MUC6 was not detected ( Figure 2C) . Thus, the initial tumors derived from HPDEC6-tre EMR cells resemble human PDACs in terms of microscopic histology and immunohistochemical expression pattern.
Subsequently, we examined regulation of transgenes in vivo by immunohistochemical detection of MYC protein. The initial tumors which should express EMR showed strong staining of MYC, whereas no expression was detected in the epithelial cells in the tissues remaining after DOX administration for 60 days. Staining for Ki67 indicated that repression of the oncogenes reduced cell proliferation ( Figure 2B ). These results confirmed that regulation of oncogene expression also functioned in vivo as well as in vitro.
MYC reexpression was detected at as early as 6 days after DOX withdrawal and significant increase of Ki-67 positive cells was detected at day 12, when overt tumor growth was observed. Mixed histology composed of simple columnar epithelium, well-differentiated adenocarcinomas and undifferentiated carcinomas was observed at day 21. The population of undifferentiated cells showed strong staining of MYC and Ki67 was present, whereas staining of CK19 and MUC1 was very weak ( Figure 2D ). In contrast, the cells of simple epithelium were negative for MYC and Ki67 and positive for CK19 and/or MUC1. Intriguingly, the cells used for transplantation were near diploid, and 45% (9/20) were normal diploid (Supplementary  Table 1 , available at Carcinogenesis Online), although it has been reported that HPV16 E6 and E7 readily induce chromosomal instability and tetraploidy (14) (15) (16) . Taken together, these results suggest that E6E7, oncogenic RAS and MYC are sufficient for tumorigenic transformation of primary HPDECs without further genetic alterations.
Immortalization of normal HPDECs
As we recently found that a ROCK inhibitor, Y27632, could inhibit keratinocyte differentiation through a novel NOTCH-ROCK pathway (17), we applied it to the reported medium for HPDEC culture. With the modified method, plating efficiencies of HPDECs were remarkably improved, but they eventually stopped growing after 9-38 population doublings depending on cell batches ( Figure 3A and B) . As senescence of normal human epithelial cells in regular culture conditions is caused by activation of RB and telomere shorting, we tried to immortalize the cells by activating telomerase through transduction of TERT, and by inactivating the pRB pathway with mutant CDK4 (CDK4
R24C
, an inhibitor resistant form of CDK4) and cyclin D1, into primary HPDECs with lentiviral vectors (18) . With this strategy, we could immortalize pooled populations of HPDEC-4, -6, -8 and -10. The combination of CDK4
, cyclin D1 and TERT (K4DT) clearly extended the life span over 40 population doublings and virtually immortalized HPDEC10 cells, whereas TERT alone hardly extend the life span ( Figure 3A) . Expression of the transgenes was confirmed by immunoblotting ( Figure 3B ). The immortalized HPDECs, as well as the primary cells, expressed cytokeratin 19 and E-cadherin ( Figure 3C ). Among them karyotype of HPDEC4-K4DT, HPDEC8-K4DT and HPDEC10-K4DT cells were analyzed and revealed that the majority of the cells were normal diploid (Supplementary Table 1 , available at Carcinogenesis Online), indicating this is an efficient strategy to immortalize normal HPDECs with minimal alteration of the genetic background.
In three-dimensional culture with type I collagen as the extracellular matrix, HPDEC4-K4DT cells could form duct-like structures in the gel (Figure 3D ), suggesting retention of a biological characteristic of HPDECs after immortalization. This could be a good tool to examine early carcinogenic events. G12V and MYC Since HPDEC4-K4DT cells were pooled populations established from primary culture of pancreatic tissue, proliferation of mesenchymal cells sometimes compromised that of epithelial cells, although the majority of HPDEC4-K4DT cells appeared to be epithelial in nature.
Tumorigenic transformation of HPDEC4-K4DT cells with transduction of p53-specific shRNA, KRAS
To remove mesenchymal cells, we cloned epithelial cell lines by limiting dilution. Then, we examined the effects of several oncogenes relevant to pancreatic carcinogenesis on the HPDEC4-B7 cell line, a purified epithelial cell line with normal diploidy. Since, the pRB pathway was already inactivated and telomerase activated in the cells, we tested three genetic alterations; inactivation of p53 using shRNA, 6 cells). One mouse was administered with DOX from day 0 as described in Figure 1D (black closed circles). Among the other six mice, one mouse was killed at day 26 as mean tumor volume exceeded 500 mm 3 (red closed squares) and five mice were administered with DOX from day 20 (white arrowhead) until day 31 when all the tumors regressed almost completely. Then DOX administration to four mice was discontinued at day 32 (black arrowhead), and the mice were killed at different time points introduction of oncogenic KRAS and altered expression of MYC. Combinations of p53-specific shRNA (p53shRNA), KRAS G12V and MYC were serially transduced into HPDEC4-B7 cells. Expression of KRAS, MYC and downregulation of p53 were confirmed by western blotting. The expression levels of transgenes were comparable with those of pancreatic cancer cell lines ( Figure 4A) .
In three-dimensional culture, p53 shRNA-expressing HPDEC4-B7 cells formed larger duct-like structures than control shRNA-expressing cells, which formed similar duct-like structures as the parental pooled HPDEC4-K4DT cells ( Figure 4B ). In accordance with the larger duct-like structures formed by HPDEC4-B7-p53shRNA cells, most showed Ki67 staining. To examine effects of KRAS G12V expression, we compared HPDEC4-B7-p53shRNA and HPDEC4-B7-p53shRNA-KRAS G12V cells, since oncogenic RAS might further induce p53 expression (19) . With KRAS G12V expression, PanIN-like structures were recapitulated and most of p53shRNA-KRAS G12V cells were positive for Ki-67 staining ( Figure 4B and C) . In this system, the cells already express KRAS G12V before being embedded in the gel, which is not the real situation for early events in carcinogenesis. So we also tried conditional KRAS G12V expression by DOX in 3D culture, but failed to observe formation of PanIN-like structures, although induction of KRAS G12V did support faster proliferation of cells in monolayer culture (Supplementary Figure 2 , available at Carcinogenesis Online).
To examine tumorigenic ability, 1 × 10 6 cells were injected subcutaneously into nude mice. HPDEC4-B7-p53shRNA-KRAS G12V -MYC T58A -expressing cells formed tumors within 2 months, whereas p53shRNA-and KRAS
G12V
-expressing cells formed tumors only after a long latent period ( Figure 4D ). Tumors derived from HPDEC4-B7 cells histologically were poorly differentiated adenocarcinomas and expressed MUC1/MUC5AC as HPDEC6-tre EMR cells did ( Figure 4E ). The other combinations of the transgenes did not confer tumorigenicity on the cells ( Figure 4D , Table I ).
Notably, 40% (8/20) of HPDEC4-B7-p53shRNA-KRAS G12V -MYC T58A cells were normal diploid (Supplementary Table 1 , available at Carcinogenesis Online). These results again indicate that KRAS and MYC on a background of inactivation of pRB and p53 pathways and active telomerase are sufficient for tumorigenic transformation of normal HPDECs without further genetic alterations.
Discussion
Establishment and in vitro culture of normal human pancreatic cells is important not only for determination of genetic alterations required for malignant transformation but also as ideal controls for identifying therapeutic targets specific for cancer cells. However, in vitro cultures of normal human pancreatic cells are very limited. Thus, most in vitro models for human PDACs have utilized established cancer cell lines. Nevertheless, there are a few human pancreatic epithelial cell lines immortalized with HPV16 E6 and E7 or ectopic expression of TERT (9, 20) . It has been shown that HPV16 E6 and E7, oncogenic Kras G12D and SV40 small t antigen are sufficient to transform TERT-immortalized HPDECs, and oncogenic KRAS alone can transform human pancreatic epithelial cells preimmortalized with HPV16 E6 and E7 (20, 21) . In the present report, we document that HPV16 E6 and E7, oncogenic RAS and MYC are sufficient to transform primary normal HPDECs. Furthermore, oncogenic RAS and inactivation of p53 are sufficient to transform HPDECs immortalized with CDK4
R24C
, cyclin D1 and TERT. All these results suggest that the number of genetic alterations required for malignant transformation is much smaller than the average of 48 alterations detected by global direct sequencing (22, 23) .
Numerous genetically engineered mouse models mimicking PanINs, intraductal papillary mucinous neoplasm, mucinous cystic neoplasms and PDACs have been successfully developed in recent years (5, (24) (25) (26) (27) . However, in vitro cultures of the human counterparts are not available. No study has succeeded in recapitulating precancerous lesions ex vivo. Better understanding of the genetics of precancerous lesions is essential for their early detection and prophylaxis. In this study, we succeeded in reconstructing ductal structures consisting of simple columnar epithelium with primary HPDECs, conditionally expressing four oncogenes sufficient for malignant transformation. From the quasinormal duct structures, development of PDACs through PanIN-like structures could be observed. Our methodology described in here could be applied to many other cell types, since we have demonstrated that HPV16 E6 and E7, oncogenic RAS and MYC are sufficient to transform different types of normal human cells (6, 8, 28) .
Four genes, KRAS, p16/CDKN2A, p53 and DPC4/SMAD4 are most commonly mutated or inactivated in PDACs. These are classified as driver alterations for PDAC development. In the majority of not only PDACs but also many other cancers, telomerase is activated and overexpression of MYC is observed. The tumors in this report presented some typical features of PDAC, even when etiologically irrelevant HPV16 oncogenes were used for transformation (29) . This might not be surprising since the viral oncogenes can mimic frequent alterations found in PDACs, namely E6 targets p53 for degradation and activates telomerase and E7 binds and inactivates pRB. Our tumorigenic cells harbored normal diploid or near diploid chromosomes, suggesting combinations of these transgenes are sufficient for malignant transformation without further genetic alteration. The experimental results allow us to conclude that the mechanisms of how the two major tumor suppressor pathways are inactivated and the A novel human cancer xenograft model for pancreatic duct adenocarcinoma telomerase is activated, do not greatly affect the resultant phenotypes of the tumors.
On the other hand, transduction of p53shRNA and KRAS
G12V
in HPDECs immortalized with CDK4 R24C , cyclin D1 and TERT also formed tumors but only after a long latent period. Thus, it is clear that MYC expression facilitated tumor formation. This result is consistent with a previous report that HPV16 E6/E7 and oncogenic KRAS-expressing pancreatic cells showed inconsistent and rather weak tumorigenic potential (21) . In the literature, resultant tumorigenic cells have been reported to show activation of AKT and the nuclear factor-κB pathway, which are also observed in PDACs (30, 31) . Overexpression of NFAT, activation of NOTCH signaling and Wnt/beta-catenin signaling are further features of PDACs (32) (33) (34) . The available findings point to MYC as a possible convergent downstream target of these different pathways. Indeed, numerous studies have revealed that MYC gene amplification and overexpression contribute to malignant phenotype, and to progression of tumors (35, 36) .
We closely examined the remaining tissue after tumor regression by DOX administration in order to confirm that no tumor cells remained. Surprisingly, many ductal structures consisting of simple columnar epithelium were apparent. During regression, most tumor cells exhibited features of apoptotic cell death upon DOX administration (Supplementary Figure 3 , available at Carcinogenesis Online). However, some survived to reform quasinormal ductal structures. Such cells were histologically attached to the basement membrane-like structures. Therefore, it is possible that only cells in a niche which can support survival of normal cells remained. These results might have important implications. Once driver oncogenes could be completely shut-off with specific inhibitors, tumor cells could reverse to normal. Reconstitution of normal tissue architectures of human cells ex vivo could be generally obtained by transplantation of the cells in the renal capsule of immunodeficient mice. However, our model system with reversible control of oncogene expression, to our knowledge for the first time, enabled quasinormal human pancreatic duct tissues to be formed subcutaneously in mice.
In recent years, development of drugs targeting RAS and MYC has been reported (37) (38) (39) . However, normal cells could relapse when administration of the drugs was terminated. This seems to be the situation with many kinase inhibitors, even in the greatest success case of chronic myeloid leukemia treated with imatinib mesylate (Gleevec). To overcome such relapse, considerations of oncogene addiction and synthetic lethality have been emphasized to develop new therapeutic drugs (40) . Indeed, the use of experimentally immortalized and transformed mammary epithelial cells has succeeded in identifying selective inhibitors of cancer stem cells using high-throughput screening (41) . Since our methodology allows propagation of both normal and cancer-initiating cells under the same conditions in vitro, it should provide an ideal set of cells for screening of drugs for this purpose. Also it enabled de novo development of PDAC from preformed quasinormal human tissues and might be applicable to carcinogenesis models of any cancers. 
